Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IQWIG

- PMLiVE

Novartis wins third NICE recommendation for Lucentis

Gains final backing to treat NHS patients with macular oedema

Former NICE chair joins board of biotech

Sir Michael Rawlins joins board of Intra-Cellular Therapeutics

National Institute for Health and Care Excellence NICE logo

NICE recommends Astellas’ Betmiga for overactive bladder

Final draft guidance recommends Vesicare successor

- PMLiVE

Novo Nordisk: Strict US regulation threatens innovation

Warning from CEO Sorensen comes after Tresiba and Ryzodeg fail to win FDA approval

- PMLiVE

The impact of Hollande’s healthcare reforms in France

A tougher environment for pharma, with market access and regulatory challenges

- PMLiVE

Value-based pricing “not in patient interest”

Think-tank 2020health calls for rethink of UK drug pricing plans

- PMLiVE

Roche survey says Scottish cancer patients moving house to get treatment

But NHS Scotland hits back at report's "extremely dubious" findings

- PMLiVE

NICE tasked with speeding NHS uptake of new technology

Expanded role will see it takeover the work of the NHS Technology Adoption Centre

Novartis building

NICE turns down Novartis’ blood cancer drug Jakavi

Uncertainties remain about drug’s cost-effectiveness, according to final draft guidance

- PMLiVE

Boehringer: Tough HTA threatens future of German research

Drug pricing system is stifling innovation says pharma company

- PMLiVE

NHS Alliance policy director to collaborate with Packer Forbes

Michael Sobanja to offer advice on market access challenges

Novartis day

Xolair gets asthma green light from NICE

Final guidance recommends Novartis drug for severe persistent asthma 

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links